Vertex Pharmaceuticals Inc. files DEF 14A with executive compensation details

Ticker: VRTX · Form: DEF 14A · Filed: Apr 4, 2024 · CIK: 875320

Sentiment: neutral

Topics: Vertex Pharmaceuticals, DEF 14A, Executive Compensation, Reshma Kewalramani, Pharmaceuticals

TL;DR

<b>Vertex Pharmaceuticals Inc. filed its DEF 14A detailing executive compensation for the 2023 fiscal year.</b>

AI Summary

VERTEX PHARMACEUTICALS INC / MA (VRTX) filed a Proxy Statement (DEF 14A) with the SEC on April 4, 2024. Vertex Pharmaceuticals Inc. filed a DEF 14A on April 4, 2024. The filing covers the fiscal year ending December 31, 2023. Key executive compensation data for Reshma Kewalramani is included. The company is incorporated in Massachusetts (MA). The standard industrial classification is Pharmaceutical Preparations [2834].

Why It Matters

For investors and stakeholders tracking VERTEX PHARMACEUTICALS INC / MA, this filing contains several important signals. This DEF 14A filing provides crucial details on the compensation packages for Vertex's top executives, including Reshma Kewalramani, which is important for shareholders to understand executive incentives and company performance alignment. As a pharmaceutical company, understanding executive compensation can offer insights into the company's strategic priorities and its investment in leadership, particularly in areas like drug development and commercialization.

Risk Assessment

Risk Level: low — VERTEX PHARMACEUTICALS INC / MA shows low risk based on this filing. The filing is a routine DEF 14A, providing standard disclosures on executive compensation and corporate governance, with no immediate red flags or significant changes indicated.

Analyst Insight

Shareholders should review the executive compensation details to assess alignment with company performance and strategic goals.

Executive Compensation

NameTitleTotal Compensation
Reshma KewalramaniMember

Key Numbers

Key Players & Entities

FAQ

When did VERTEX PHARMACEUTICALS INC / MA file this DEF 14A?

VERTEX PHARMACEUTICALS INC / MA filed this Proxy Statement (DEF 14A) with the SEC on April 4, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by VERTEX PHARMACEUTICALS INC / MA (VRTX).

Where can I read the original DEF 14A filing from VERTEX PHARMACEUTICALS INC / MA?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by VERTEX PHARMACEUTICALS INC / MA.

What are the key takeaways from VERTEX PHARMACEUTICALS INC / MA's DEF 14A?

VERTEX PHARMACEUTICALS INC / MA filed this DEF 14A on April 4, 2024. Key takeaways: Vertex Pharmaceuticals Inc. filed a DEF 14A on April 4, 2024.. The filing covers the fiscal year ending December 31, 2023.. Key executive compensation data for Reshma Kewalramani is included..

Is VERTEX PHARMACEUTICALS INC / MA a risky investment based on this filing?

Based on this DEF 14A, VERTEX PHARMACEUTICALS INC / MA presents a relatively low-risk profile. The filing is a routine DEF 14A, providing standard disclosures on executive compensation and corporate governance, with no immediate red flags or significant changes indicated.

What should investors do after reading VERTEX PHARMACEUTICALS INC / MA's DEF 14A?

Shareholders should review the executive compensation details to assess alignment with company performance and strategic goals. The overall sentiment from this filing is neutral.

How does VERTEX PHARMACEUTICALS INC / MA compare to its industry peers?

Vertex Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development and commercialization of medicines.

Are there regulatory concerns for VERTEX PHARMACEUTICALS INC / MA?

The DEF 14A filing is a regulatory requirement under the Securities Exchange Act of 1934, mandating public companies to provide detailed information on corporate governance and executive compensation.

Industry Context

Vertex Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development and commercialization of medicines.

Regulatory Implications

The DEF 14A filing is a regulatory requirement under the Securities Exchange Act of 1934, mandating public companies to provide detailed information on corporate governance and executive compensation.

What Investors Should Do

  1. Review executive compensation packages for key personnel like Reshma Kewalramani.
  2. Analyze the breakdown of compensation components (e.g., equity awards, salary).
  3. Assess the alignment of executive pay with company performance metrics and strategic objectives.

Key Dates

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard disclosure document. Specific comparative data from a previous filing is not directly available in this extract.

Filing Stats: 4,525 words · 18 min read · ~15 pages · Grade level 13.3 · Accepted 2024-04-04 16:01:33

Key Financial Figures

Filing Documents

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 VERTEX PHARMACEUTICALS INCORPORATED (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. A Letter from our Executive Chairman and Chief Executive Officer Dear Shareholders: 2023 was a transformative year for Vertex. We extended our leadership in cystic fibrosis ("CF"), expanded into new disease areas with CASGEVY regulatory approvals and commercial launches for severe sickle cell disease ("SCD") and transfusion-dependent beta thalassemia ("TDT") in multiple regions, and continued the rapid advancement of our broad pipeline, which offers the potential for multiple commercial launch opportunities in disease areas outside of CF over the next few years. We believe that these important advances in 2023, combined with our continued excellent financial performance, fuel a new era of medical and commercial diversification for Vertex and significant value creation for patients and shareholders alike. Net product revenues from our CF medicines grew to $9.87 billion in 2023, representing an 11% increase from 2022. We continued to invest significantly in innovation — both internal and external — to support our differentiated research and development ("R&D") approach, focused on validated targets that address causal human biology, biomarkers that translate from bench to bedside, efficient development and regulatory pathways, and product candidates with transformative potential. Our differentiated R&D strategy has continued to deliver. We have obtained approvals for the first CRISPR/Cas9 gene-edited cell therapy in the world for the treatment of SCD and TDT and we have also delivered positive Phase 3 results for VX-548, our novel NaV1.8 pain signal inhibitor in acute pain, and for our triple combination of vanzacaftor/tezacaftor/deutivacaftor in CF. Our programs in neuropathic pain, APOL1-mediated kidney disease, and type 1 diabetes have all passed the proof-of-concept stage and represent additional multi-billion-dollar market potential. In total, our clinical-stage pipeline now spans 10 disease areas and multiple modalities, including small molecules, oligonucleotides, and cell and genetic therapies. Along with developing and commercializing transformative medicines for people with serious diseases, we continue to support patients, our local communities, and our employees. Last year, Vertex celebrated its 15 th Global Day of Service, with participation by 60% of employees contributing nearly 8,300 hours of volunteer work across more than 125 projects with 73 non-profit groups. In addition, Vertex and the Vertex Foundation provided more than $42 million in charitable donations, with a focus on education, innovation, health, and our local communities. We remain committed to recruiting, retaining, and developing highly talented employees from a diverse range of backgrounds, promoting our employees' continued well-being and professional development, and nurturing our unique culture, which has enabled us to deliver multiple transformative medicines to patients. Our efforts continue to be recognized externally, and in 2023, Vertex was named to Fortune 100 Best Companies to Work For 2023, Forbes Best Employers for Diversity 2023, and 2023 PEOPLE Companies that Care. In summary, consistent execution of our R&D and corporate strategy continues to deliver strong and durable financial results, setting up significant and sustainable long-term growth for the business. We are treating more people with CF around the world and are working to translate the historic regulatory approvals for CASGEVY in SCD and TDT into real world patient benefit. We are also preparing for additional potential near-term submissions, approvals, and launches, including for vanzacaftor/tezacaftor/deutivacaftor in CF and VX-548 in acute pain, both of which have the potential to dramatically improve patient lives and represent significant opportunities for Vertex. In parallel, we are progressing the next wave of innovation and look forward to bringing additional first-in-class or best-in-class medicines to people living with serious diseases. This is an extraordinarily exciting time for Vertex and, as Executive Chairman and Chief Executive Officer, we are commi

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing